Related Experiment Videos

[A case of cerebrotendinous xanthomatosis with convulsive seizures]

K Matsumuro1, K Takahashi, H Matsumoto

  • 1Department of Neurology, Okatsu Hospital, Kagoshima.

Insights

Chenodiol treatment improved seizures and cholestanol levels in a patient with cerebrotendinous xanthomatosis (CTX). However, brain MRI abnormalities persisted, indicating irreversible neurological damage from this rare genetic disorder.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder.
  • Characterized by impaired bile acid synthesis, leading to accumulation of cholestanol and cholesterol.
  • Often presents with neurological and psychiatric symptoms, cataracts, and tendinous xanthomas.

Observation:

  • A 35-year-old male with a history of intractable seizures, mental retardation, cataracts, and Achilles tendon swellings.
  • Elevated serum cholestanol levels and cholestanol/cholesterol ratio.
  • EEG abnormalities and MRI findings of globus pallidus and white matter lesions.

Findings:

  • Oral chenodeoxycholic acid (CDCA) therapy improved EEG, reduced serum cholestanol, and controlled seizures.
  • Neurological symptoms and MRI-detected brain lesions showed no improvement, suggesting irreversible damage.
  • CTX is identified as a potential cause of symptomatic epilepsy, with 14 of 144 reviewed cases experiencing seizures.

Implications:

  • CDCA therapy can manage biochemical and seizure manifestations of CTX.
  • Early diagnosis and treatment are crucial to prevent irreversible neurological damage.
  • Highlights the importance of considering CTX in the differential diagnosis of epilepsy with specific clinical features.

Related Concept Videos